Arnal-García C,del Campo C,-Jorrin M,López-Real AM,Lema-Devesa C,Llopis N,Sanchez-de la Rosa N .2014 .Long-term effectiveness of glatiramer acetate in clinical practice conditions. J Clin Neurosci, 21(12) : 2212-2218.
Brown FS,Glasmacher SA,Kearns PK,MacDougall N,Hunt D,Connick P,Chandran S P .2020 .Systematic review of prediction models in relapsing remitting multiple sclerosis. PLoS One, 15(5) : e0233575.
Barzegar M,Najdaghi S,Afshari-Safavi A,Nehzat N,Mirmosayyeb O,Shaygannejad V .2021 .Early predictors of conversion to secondary progressive multiple sclerosis. Mult Scler Relat Disord., 54 : 103115.
Brück W,Gold R,Lund BT,Oreja-Guevara C,Prat A,Rudick R,Leist TP .2019 .Therapeutic decisions in multiple sclerosis: Moving beyond efficacy. J Neurol Sci, 405 : 116424.
Boziki MK,Mentis AFA,Shumilina M,Makshakov G,Kalnins G,Grigoriadis N G .2020 .The role of telemedicine in multiple sclerosis: A systematic review. J Telemed Telecare, 27(4) : 203-213.
Buron MD,Fernández Ó,Giovannoni G Gold R,Hemmer B,Montalban X,Oreja-Guevara C .2022 .A global survey of healthcare professionals' experiences and attitudes toward digital tools in multiple sclerosis care. Mult Scler Relat Disord, 63 : 103839.
Benedict RH,Zivadinov R .2011 .Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol, 7 : 332-342.
Costello F,Stüve O,Weber MS,Zamvil SS,Frohman E .2007 .Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice. Curr Opin Neurol, 20(3) : 281-285.
Chen C,Zhang E,Zhu C,Wei R,Ma L,Dong X,Liu Z X .2023 .Comparative efficacy and safety of diseasemodifying therapies in patients with relapsing multiple sclerosis: a systematic review and network metaanalysis. J Am Pharm Assoc, 63(1) : 8-22.
Cree BA,Arnold DL,Chataway J,Chitnis T,Fox RJ,Pozo Ramajo A,Lassmann H Ramajo A .2021 .Secondary progressive multiple sclerosis: New insights. Neurology, 97(8) : 378-388.
Caseby SCL,Woodhouse FA,Montgomery SM,Kroes M. A,Duddy ME .2022 .Transition to secondary progressive multiple sclerosis: The consequences for patients and healthcare systems, a healthcare professional survey. Health Sci Rep, 5(1) : e474.
Cross AH,Naismith RT .2014 .Established and novel disease-modifying treatments in multiple sclerosis. J Intern Med, 275(4) : 350-363.
Cree BAC,Bennett JL,Kim HJ,Weinshenker BG,Pittock SJ,Wingerchuk DM,Traboulsee AL DM .2021 .Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): A double-blind, randomised placebo-controlled phase 2/3 trial. The Lancet, 394(10206) : 1352-1363.
Cohen J. A.,Rae-Grant A. .2012 .Handbook of multiple sclerosis (5th ed. , : .
Cohan SL,Lucassen EB,Romba MC,Linch SN,Stern J NH,Bar-Or A,Piccio L A .2019 .DMTs in multiple sclerosis: Mechanisms of action and recent advances. Curr Neurol Neurosci Rep, 19 : 92.
Dobson R and Giovannoni G .2019 .Multiple sclerosis-a review. Eur J Neurol, 26(1) : 27-40.
Eisner E,Drake R,Lobban F,Bucci S,Emsley R,Barrowclough C .2018 .Comparing early signs and basic symptoms as methods for predicting psychotic relapse in clinical practice. Schizophr. Res., 192 : 124-130.
Filipi M and Jack S .2020 .Interferons in the treatment of multiple sclerosis: A clinical efficacy, safety, and tolerability update. Int J MS Care, 22(4) : 165-172.
Giovannoni G,Lang S,Wolff R,Duffy S,Hyde R,Kinter E,Kleijnen J .2020 .A systematic review and mixed treatment comparison of pharmaceutical interventions for multiple sclerosis. Neurol Ther, 9 : 359-374.
Gabelić T,Barun B,Adamec I,Krbot Skorić M and Habek M I .2021 .Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis. Hum Vaccin Immunother, 17(11) : 4345-4362.
Hauser SL,Bar-Or A,Comi G,Giovannoni G,Hartung H P B,Kappos L B .2017 .Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New N Engl J Med, 376(3) : 221-234.
Kieseier BC,Stüve O .2011 .Combination therapy in MS-still a valid strategy. Nat Rev Neurol, 7(12) : 659-660.
Kleiter I,Ayzenberg I,Havla J,Lukas C,Penner IK,Stadelmann C,Linker RA C .2020 .The transitional phase of multiple sclerosis: Characterization and conceptual framework. Mult Scler Relat Disord, 44 : 102242.
La Mantia L,Di Pietrantonj C,Rovaris M,Rigon G,Berardo S,Vaona F,A F .2016 .Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev., 11(11) : CD009333.
Lang GGS,Wolff R,Duffy S,Wakeford RHEKC,Kleijnen MPSJ .2020 .A systematic review and mixed treatment comparison of pharmaceutical interventions for multiple sclerosis. Mult Scler, 2 : 4-7.
Li R,Patterson KR,Bar-Or A .2018 .Reassessing B cell contributions in multiple sclerosis. Nature Immunology, 19 : 696-707.
Michel MC,Staskin D MC .2022 .Study designs for evaluation of combination treatment: Focus on individual patient benefit. Biomedicines, 10(2) : 270.
Panitch H Milo R .2011 .Combination therapy in multiple sclerosis. J Neuroimmunol, 231(1-2) : 23-31.
Mierau M,Schoels M,Gonda G,Fuchs J,Aletaha D,Smolen JS .2007 .Assessing remission in clinical practice. Rheumatol., 46(6) : 975-9.
Marrie RA,Reider N,Cohen J,Stuve O,Trojano M,Sørensen PS,Montalban X,Scler J .2015 .A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. , 21(3) : 263-281.
Macías Islas MÁ,Ciampi E .2019 .Assessment and management of cognitive impairment in multiple sclerosis: Current understanding and future directions. J Neurol, 266(1) : 35-44.
.2022 .Multiple sclerosis: Management (NICE Guideline NG220. , : .
Ontaneda D,Fox RJ .2015 .Progressive multiple sclerosis. Curr Opin Neurol, 28(3) : 237-243.
Stuart WH .2007 .Combination therapy for the treatment of multiple sclerosis: Challenges and opportunities. Curr Med Res Opin, 23(6) : 1199-1208.
Sorensen PS,Magyari M,Sellebjerg F M .2023 .An update on combination therapies for multiple sclerosis: where are we now?. Expert Rev Neurother, 23(12) : 1173-1187.
Saleem S,Anwar A,Fayyaz M,Anwer F and Anwar F M .2019 .An overview of therapeutic options in relapsingremitting multiple sclerosis. Cureus, 11(7) : .
Zajecka JM .2013 .Residual symptoms and relapse: mood, cognitive symptoms, and sleep disturbances. J Clin Psychiatry, 74(suppl 2) : 18130.
Sempik I,Dziadkowiak E,Moreira H,Zimny A,Pokryszko-Dragan A. .2024 .Primary progressive multiple sclerosis-a key to understanding and managing disease progression. Int J Mol Sci, 25(16) : 8751.
Schneider R and Oh J .2022 .Bruton's tyrosine kinase inhibition in multiple sclerosis. Curr Neurol Neurosci Rep, 22(11) : 721-734.
Solaro C,Trabucco E,Uccelli MM .2020 .Pain and multiple sclerosis: Pathophysiology and treatment. Curr Neurol Neurosci Rep, 20 : 58.
Tselis A,Khan O,Lisak RP .2007 .Glatiramer acetate in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat, 3(2) : 259-267.
Thompson AJ,Banwell BL,Barkhof F,Carroll WM,Coetzee T,Comi G,Cohen JA .2018 .Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol, 17(2) : 162-173.
Wingerchuk DM,Carter JL DM .2014 .Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. In Mayo Clinic Proceedings. Elsevier, 89(2) : 225-240.
Walton C,King R,Rechtman L,Kaye W,Leray E,Marrie RA,Wallin M .2020 .Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler, 26(14) : 1816-1821.
Wallin MT,Culpepper WJ,Campbell JD,Nelson LM,Langer-Gould A,Marrie RA,Kaye WE .2019 .The prevalence of MS in the United States: A populationbased estimate using health claims data. Neurology, 92(10) : e1029-e1040.
Ziemssen T,Rauer S,Stadelmann C,Henze T,Koehler J,Penner IK,Meuth S IK .2015 .Evaluation of study and patient characteristics of clinical studies in primary progressive multiple sclerosis: A systematic review. PLoS One, 10(9) : e0138243.
Zettl UK,Rommer PS,Aktas O,Wagner T,Richter J,Oschmann P,Hecker M .2023 .Interferon beta-1a sc at 25 years: A mainstay in the treatment of multiple sclerosis over the period of one generation. Expert Rev Clin Immunol, 19(11) : 1343-1359.